To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
- Today’s Promising Areas of Cancer Research
- What is Cancer?
- A Broken Pipeline?
A Generation of Science at Risk
- ARISE Report
Early Career Scientists and High-Risk, High Reward Research - American Academy of Arts and Sciences
- Why We’re Losing the War on Cancer (And How To Win It)
Clifton Leaf - Fortune Magazine
June 15, 2010 > Pathways identified in metastatic lung cancer
William Y. Kim, MD (Damon Runyon-Merck Clinical Investigator ‘09-‘12) of the University of North Carolina, Chapel Hill, and colleagues reported that the SRC, PI3K and MEK1/2 kinase signaling pathways act together in metastatic lung tumors that have deletions of the tumor suppressor LKB1. These findings suggest that unique combinatorial therapies may be successful for treatment of lung cancers. The research was published in the journal Cancer Cell.